198 related articles for article (PubMed ID: 23483943)
1. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.
Besser MJ; Shoham T; Harari-Steinberg O; Zabari N; Ortenberg R; Yakirevitch A; Nagler A; Loewenthal R; Schachter J; Markel G
PLoS One; 2013; 8(3):e57922. PubMed ID: 23483943
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
3. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.
Carrega P; Pezzino G; Queirolo P; Bonaccorsi I; Falco M; Vita G; Pende D; Misefari A; Moretta A; Mingari MC; Moretta L; Ferlazzo G
PLoS One; 2009 Dec; 4(12):e8132. PubMed ID: 19997637
[TBL] [Abstract][Full Text] [Related]
5. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
6. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.
Markel G; Seidman R; Besser MJ; Zabari N; Ortenberg R; Shapira R; Treves AJ; Loewenthal R; Orenstein A; Nagler A; Schachter J
PLoS One; 2009; 4(5):e5597. PubMed ID: 19440333
[TBL] [Abstract][Full Text] [Related]
7. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
Wang W; Erbe AK; Alderson KA; Phillips E; Gallenberger M; Gan J; Campana D; Hank JA; Sondel PM
Cancer Immunol Immunother; 2016 Sep; 65(9):1047-59. PubMed ID: 27392940
[TBL] [Abstract][Full Text] [Related]
8. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
Lakshmikanth T; Burke S; Ali TH; Kimpfler S; Ursini F; Ruggeri L; Capanni M; Umansky V; Paschen A; Sucker A; Pende D; Groh V; Biassoni R; Höglund P; Kato M; Shibuya K; Schadendorf D; Anichini A; Ferrone S; Velardi A; Kärre K; Shibuya A; Carbone E; Colucci F
J Clin Invest; 2009 May; 119(5):1251-63. PubMed ID: 19349689
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell crossmatch: functional analysis of inhibitory killer immunoglobulin-like receptors and their HLA ligands.
Han M; Fallena M; Guo Y; Stastny P
Hum Immunol; 2007 Jun; 68(6):507-13. PubMed ID: 17509450
[TBL] [Abstract][Full Text] [Related]
10. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
11. Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro.
Ahn YO; Kim S; Kim TM; Song EY; Park MH; Heo DS
J Immunother; 2013 Sep; 36(7):373-81. PubMed ID: 23924789
[TBL] [Abstract][Full Text] [Related]
12. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
13. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
[TBL] [Abstract][Full Text] [Related]
14. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
[TBL] [Abstract][Full Text] [Related]
15. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E
Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811
[TBL] [Abstract][Full Text] [Related]
16. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
17. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro.
Rose MJ; Brooks AG; Stewart LA; Nguyen TH; Schwarer AP
J Immunol; 2009 Oct; 183(7):4502-8. PubMed ID: 19748981
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
19. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
20. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
Gooneratne SL; Center RJ; Kent SJ; Parsons MS
Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
